Maraviroc in the treatment of HIV infection.

Drug Design, Development and Therapy
Neelanjana Ray

Abstract

While a successful HIV vaccine will likely take several more years to become a reality, many anti-retroviral (ARV) drugs are currently available to treat HIV infection, and their efficacious use has improved the quality of life and life expectancy of millions of HIV-infected individuals. A recent addition to these ARVs is a new class of drug that targets the HIV entry process by interfering with the action of the CCR5 coreceptor. The first licensed member of this class is a drug called maraviroc, which is also the first ARV that targets a cellular rather than a viral protein. Several other CCR5 antagonists with varied mechanisms of action are being developed. Key issues with the use of these drugs include determining their potential for use in treatment-naïve versus treatment-experienced patients, the development of sensitive coreceptor phenotyping assays to determine patient eligibility, and finally monitoring the emergence of resistant viruses and their mechanisms of resistance. This review summarizes the preclinical and clinical development of maraviroc as well as studies of HIV resistance to this drug both in vitro and in patients. In addition, a range of diverse CCR5 antagonists currently under development, are also discus...Continue Reading

References

Aug 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·B T KorberA S Lapedes
Oct 23, 1997·Proceedings of the National Academy of Sciences of the United States of America·A G YangS Chen
Apr 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·T DragicJ P Moore
Jan 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Alexandra TrkolaJohn P Moore
Oct 14, 2003·Nature Biotechnology·V McNeil CoffieldLishan Su
Nov 17, 2004·Proceedings of the National Academy of Sciences of the United States of America·Oliver HartleyRobin Offord
Jan 22, 2005·The New England Journal of Medicine·John P Moore
Feb 18, 2005·The Journal of Infectious Diseases·Graeme J MoyleBrian G Gazzard
Jun 25, 2005·Current Protein & Peptide Science·Oliver Hartley, Robin E Offord
Jul 5, 2005·The Journal of Infectious Diseases·Zabrina L BrummeP Richard Harrigan
Aug 9, 2005·Biochemical and Biophysical Research Communications·Mala ManiSrinivasan Chandrasegaran
Oct 19, 2005·The Journal of Experimental Medicine·William G GlassPhilip M Murphy
Jan 19, 2006·The Journal of Experimental Medicine·William G GlassPhilip M Murphy
Jan 27, 2006·The EMBO Journal·Paolo Lusso
Feb 24, 2006·Virology·Christoph SeibertThomas P Sakmar
Mar 30, 2006·Antimicrobial Agents and Chemotherapy·Tina M Kish-CataloneAnthony L DeVico
Sep 9, 2006·The Journal of Infectious Diseases·Peter W HuntSteven G Deeks
Nov 23, 2006·Antimicrobial Agents and Chemotherapy·Masanori BabaKatsunori Takashima
Jan 24, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Timothy J WilkinRoy M Gulick
Dec 11, 2007·Nature Biotechnology·John J RossiDonald B Kohn

❮ Previous
Next ❯

Citations

Jul 16, 2010·Journal of Nanobiotechnology·Humberto H LaraCristina Rodriguez-Padilla
May 30, 2020·AIDS Research and Human Retroviruses·Tennison Onoriode DigbanLarry Chikwelu Obi
Jul 2, 2019·Acta Pharmaceutica : a Quarterly Journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, Dealing with All Branches of Pharmacy and Allied Sciences·Jakub VysloužilDavid Vetchý

❮ Previous
Next ❯

Software Mentioned

MOTIVATE
geno2
WebPSSM
Webcat

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved